
简介:
- 作者: Shuai Lu, Xi-xiu Xie,Lei Zhao, Bin Wang, Jie Zhu, Ting-rui Yang, Guang-wen Yang, Mei Ji, Cui-ping Lv, Jian Xue, Er-hei Dai, Xi-ming Fu, Dong-qun Liu, Lun Zhang, Sheng-jie Hou, Xiao-lin Yu, Yu-ling Wang, Hui-xia Gao, Xue-han Shi, Chang-wen Ke, Bi-xia Ke, Chun-guo Jiang, and Rui-tian Liu
- 杂志: Cell Reports
- Doi: https://www.doi.org/10.1016/j.celrep.2020.108666
- 出版日期: 2021 Jan 26
论文中使用的产品/服务
Quotation shows PackGene:D614 SARS-CoV-2 pseudoviruses (Cat#LV-nCov1); G614 SARS-CoV-2 pseudoviruses (Cat#LV-nCov1); ACE2-239T cells (Cat#nCov-3)
Research Field:Covid-related
摘要
Although vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are under development, the antigen epitopes on the virus and their immunogenicity are poorly understood. Here, we simulate the 3D structures and predict the B cell epitopes on the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2 using structure-based approaches and validate epitope immunogenicity by immunizing mice. Almost all 33 predicted epitopes effectively induce antibody production, six of these are immunodominant epitopes in individuals, and 23 are conserved within SARS-CoV-2, SARS-CoV, and bat coronavirus RaTG13. We find that the immunodominant epitopes of individuals with domestic (China) SARS-CoV-2 are different from those of individuals with imported (Europe) SARS-CoV-2, which may be caused by mutations on the S (G614D) and N proteins. Importantly, we find several epitopes on the S protein that elicit neutralizing antibodies against D614 and G614 SARS-CoV-2, which can contribute to vaccine design against coronaviruses.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
